Frequency and prognostic value of NPM1 mutations in Sudanese acute myeloid leukemia patients
1Department of Haematology, Faculty of Medical laboratory Sciences, International University of Africa, Khartoum, Sudan. ORCID ID: 0000-0002-7797-0369.
2 Hematology and Stem Cell Technology, Al Neelain Stem Cell center, Al Neelain University, Khartoum, Sudan. ORCID ID: 0000-0003-0305-7726.
Research Article
GSC Biological and Pharmaceutical Sciences, 2021, 14(02), 181-184.
Article DOI: 10.30574/gscbps.2021.14.2.0055
Publication history:
Received on 18 January 2021; revised on 19 February 2021; accepted on 21 February 2021
Abstract:
Acute myeloid leukemia (AML) is a malignancy of proliferative, clonal, abnormally differentiated cells of the hematopoietic system, described byevolution and genetic heterogeneity. Molecular genetics of AML regarding the prognosis of patients primarily representing by NPM1. NPM1 is a nucleolar protein that placed on chromosome 5q35.1 which transported between the nucleus and cytoplasm. It is concerned in multiple functions, including ribosomal protein assembly and transport, control of centrosome duplication, and regulation of the tumor suppressor ARF & p53. NPM1 mutations that relocalize NPM1 from the nucleus into the cytoplasm are associated with development of acute myeloid leukemia. The aim of this study was to determine the frequency and shed light on the prognostic value of NPM1 mutations among Sudanese patients with acute myeloid leukemia. A cross sectional study recruited 100 patients in this study clinically diagnosed firstly (not transformed from any other malignancy) as AML patients based on the diagnostic protocol concern radioisotopecentre of Khartoum (RICK) hospital; such as morphological identification, immunophenotyping analysis, and molecular genetics, Of the 100 AML patients, 54% were newly diagnosed and 46% were admitted by chemotherapy treatment and follow up. EDTA blood or bone marrow samples were collected from patients for performing CBC, hematological studies including FAB classification, PCR protocols and sequencing. Genomic DNA was extracted from all samples using guanidine method.
NPM1 mutations detection, sequencing technique was done, then sequencing analysis by software (Mega 7 Software) revealed that there were no NPM1mutations in Sudanese AML patients. The Sudanese AML patients carry wild type NPM1.
Keywords:
Acute Myeloid Leukemia; NPM1; Sudanese
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
